Understanding why scarring happens in muscular dystrophy muscles
Official title: Understanding the Mechanisms of Fibrosis in Muscular Dystrophies
Funded at University of Florida · NIH-11370556 · Data updated 2026-11-12
Researchers are studying why scar tissue forms in muscles affected by muscular dystrophy and how to slow or reverse it in patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | July 12, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $453,403 |
| NIH project number | 5R01AR083108-04 |
| Project ID | NIH-11370556 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with muscular dystrophy, particularly Duchenne muscular dystrophy, who may benefit from future therapies targeting muscle fibrosis.
✕Less likely to help
Patients unlikely to benefit are those without muscular dystrophy or related fibrotic muscle conditions or who would not be eligible for future fibrosis-targeting therapies.
What this research studies
Muscular dystrophy can cause muscles to weaken as scar tissue builds up. This grant focuses on the cellular processes that drive this scarring and poor muscle regeneration. By looking closely at cells called myofibroblasts and a protein target called NOX4, the team hopes to uncover why fibrosis persists after injury and how to promote healthier muscle repair. The work combines genetic and drug-based approaches to understand and eventually improve muscle outcomes for people with Duchenne muscular dystrophy.
Why it matters
Potential benefit: If successful, the research could lead to new therapies that reduce scar tissue and improve muscle function in patients with muscular dystrophy.
How similar studies have gone: Previous studies have shown that targeting NOX4 can reduce fibrosis and help muscle remodeling in dystrophic models, supporting this line of investigation.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Hammers, David W — University of Florida
- Study coordinator: Hammers, David W
Related research
Other NIH-funded projects on the same topics.
-
Stopping Muscle Scarring in Muscular Dystrophies
This project explores how muscle scarring, called fibrosis, develops in muscular dystrophies like Duchenne MD, hoping to find new ways to help muscles heal better.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
-
Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring
A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.